COVID-19 Pandemic: Insights into Interactions Between SARS-CoV-2 Infection and MAFLD

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2022 Jul 25

PMID 35874945

Authors

Hanfei Chen

Qiang Chen

Affiliations

Soon will be listed here.

Abstract

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an ongoing global health pandemic. Since 2019, the pandemic continues to cast a long shadow on all aspects of our lives, bringing huge health and economic burdens to all societies. With our in-depth understanding of COVID-19, from the initial respiratory tract to the later gastrointestinal tract and cardiovascular systems, the multiorgan involvement of this infectious disease has been discovered. Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named nonalcoholic fatty liver disease (NAFLD), is a major health issue closely related to metabolic dysfunctions, affecting a quarter of the world's adult population. The association of COVID-19 with MAFLD has received increasing attention, as MAFLD is a potential risk factor for SARS-CoV-2 infection and severe COVID-19 symptoms. In this review, we provide an update on the interactions between COVID-19 and MAFLD and its underlying mechanisms.

Citing Articles

Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis From 1990 to 2021.

Lu F, Liu J, She B, Yang H, Ji F, Zhang L Liver Int. 2024; 45(4):e16120.

PMID: 39387341 PMC: 11891383. DOI: 10.1111/liv.16120.

Impact of non-alcoholic fatty liver disease on coronavirus disease 2019: A systematic review.

Moeed A, Larik M, Ali Fahim M, Rahman H, Najmi L, Changez M World J Hepatol. 2024; 16(8):1185-1198.

PMID: 39221098 PMC: 11362910. DOI: 10.4254/wjh.v16.i8.1185.

Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19.

Brilakis L, Theofilogiannakou E, Lykoudis P World J Gastroenterol. 2024; 30(11):1480-1487.

PMID: 38617460 PMC: 11008415. DOI: 10.3748/wjg.v30.i11.1480.

Implications of metabolic dysfunction associated fatty liver disease in COVID-19.

Chakraborty R, Sharma D, Kapoor D, Dwivedi A, Khabiya R, Sen S World J Clin Cases. 2023; 11(6):1275-1286.

PMID: 36926128 PMC: 10013103. DOI: 10.12998/wjcc.v11.i6.1275.

The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal Function.

Valentino M, Marzuillo P, Esposito C, Bartiromo M, Nardolillo M, Villani A J Clin Med. 2023; 12(5).

PMID: 36902824 PMC: 10003972. DOI: 10.3390/jcm12052037.

References

Mendez-Sanchez N, Bugianesi E, Gish R, Lammert F, Tilg H, Nguyen M . Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022; 7(5):388-390. DOI: 10.1016/S2468-1253(22)00062-0. View

Zhang L, Richards A, Barrasa M, Hughes S, Young R, Jaenisch R . Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci U S A. 2021; 118(21). PMC: 8166107. DOI: 10.1073/pnas.2105968118. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z . Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Med Microecol. 2021; 5:100023. PMC: 7832617. DOI: 10.1016/j.medmic.2020.100023. View

Puelles V, Lutgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L . Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. PMC: 7240771. DOI: 10.1056/NEJMc2011400. View

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

Targher G, Mantovani A, Byrne C, Wang X, Yan H, Sun Q . Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab. 2020; 46(6):505-507. PMC: 7270805. DOI: 10.1016/j.diabet.2020.06.001. View

Milic J, Barbieri S, Gozzi L, Brigo A, Beghe B, Verduri A . Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis. 2022; 9(3):ofac003. PMC: 8826155. DOI: 10.1093/ofid/ofac003. View

Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F . Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015; 21(5):739-46. DOI: 10.1016/j.cmet.2015.04.004. View

10.

Youssef M, Hussein M, Attia A, Elshazli R, Omar M, Zora G . COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies. J Med Virol. 2020; 92(10):1825-1833. PMC: 7283797. DOI: 10.1002/jmv.26055. View

11.

Rinella M, Sanyal A . Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016; 13(4):196-205. DOI: 10.1038/nrgastro.2016.3. View

12.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

13.

Ding Z, Li G, Chen L, Shu C, Song J, Wang W . Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2020; 74(6):1295-1302. PMC: 7749734. DOI: 10.1016/j.jhep.2020.12.012. View

14.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L . SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4):807-816. PMC: 7211738. DOI: 10.1016/j.jhep.2020.05.002. View

15.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

16.

Li J, Tian A, Zhu H, Chen L, Wen J, Liu W . Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19. Clin Gastroenterol Hepatol. 2022; 20(7):1553-1560.e78. PMC: 8812093. DOI: 10.1016/j.cgh.2022.01.045. View

17.

Rosser B, Gores G . Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995; 108(1):252-75. DOI: 10.1016/0016-5085(95)90032-2. View

18.

Mao R, Liang J, Shen J, Ghosh S, Zhu L, Yang H . Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020; 5(5):425-427. PMC: 7103943. DOI: 10.1016/S2468-1253(20)30076-5. View

19.

De Smet V, Verhulst S, van Grunsven L . Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2. J Hepatol. 2020; 73(4):993-995. PMC: 7253986. DOI: 10.1016/j.jhep.2020.05.030. View

20.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View